Nonhealing ulcer secondary to factor V Leiden mutation and cryofibrinogenemia

Journal of the American Academy of Dermatology

Volumn 51, Issue 5 SUPPL., 2004, Pages S194-S196

  Barrio, Victoria R ^a   Sanfilippo, Angela M ^a   Malone, Janine C ^a   Callen, Jeffrey P ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BECAPLERMIN; BLOOD CLOTTING FACTOR 5 LEIDEN; CLOPIDOGREL; METHYLPREDNISOLONE; NARCOTIC ANALGESIC AGENT; PENTOXIFYLLINE; STANOZOLOL; WARFARIN; BLOOD CLOTTING FACTOR 5;

ADULT; AMPUTATION STUMP; ARTICLE; BELOW KNEE AMPUTATION; CASE REPORT; CRYOFIBRINOGENEMIA; DISEASE COURSE; DRUG ERUPTION; DRUG RESPONSE; EVALUATION; FIBRINOGEN BLOOD LEVEL; GENERAL CONDITION IMPROVEMENT; HOMOZYGOSITY; HUMAN; LABORATORY TEST; MALE; MUTATION; PAIN; PATIENT REFERRAL; PHYSICAL EXAMINATION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PYODERMA GANGRENOSUM; SKIN BIOPSY; SKIN GRAFT; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; ULCER; ULCER HEALING; WOUND DRESSING; CRYOGLOBULINEMIA; GENETICS; HOMOZYGOTE; LEG ULCER;

ADULT; AMPUTATION STUMPS; CRYOGLOBULINEMIA; FACTOR V; HOMOZYGOTE; HUMANS; LEG ULCER; MALE; MUTATION;

EID: 16644380883     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2004.04.043     Document Type: Article

References (12)

1. R.H. Weenig, M.D. Davis, P.R. Dahl, and W.P. Su Skin ulcers misdiagnosed as pyoderma gangrenosum N Engl J Med 347 2002 1412 1418
2. W.L. Nichols, and J.A. Heit Activated protein C resistance and thrombosis Mayo Clin Proc 71 1996 897 898
3. J.S. Greengard, X. Sun, X. Xu, J.A. Fernandez, J.H. Griffin, and B. Evatt Activated protein C resistance caused by Arg506Gln mutation in factor Va Lancet 343 1994 1361 1362
4. B. Dahlback Activated protein C resistance and thrombosis: molecular mechanisms of the hypercoagulable state due to FVR506Q mutation Semin Thromb Hemost 25 1999 273 289
5. P.J. Svensson, and B. Dahlback Resistance to activated protein C as a basis for venous thrombosis N Engl J Med 330 1994 517 521
6. F.R. Rosendaal, J.P. Koster, J.P. Vandenbroucke, and P.H. Reitsma High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance) Blood 85 1995 1504 1508
7. A.D. Klein, and F.A. Kerdel Purpura and recurrent ulcers on the lower extremities: essential cryofibrinogenemia Arch Dermatol 127 1991 115 118
8. V. Falanga, R.S. Kirsner, W.H. Eaglstein, M.H. Katz, and F.A. Kerdel Stanazolol in treatment of leg ulcers due to cryofibrinogenaemia Lancet 338 1991 347 348
9. R.S. Kirsner, W.H. Eaglstein, M.H. Katz, F.A. Kerdel, and V. Falanga Stanazolol causes rapid pain relief and healing of cutaneous ulcers caused by cryofibrinogenemia J Am Acad Dermatol 28 1993 71 74
10. C. Kluft, R.M. Bertina, F.E. Preston, R.G. Malia, S.L. Blamey, and G.D. Lowe Protein C, and anticoagulant protein, is increased in healthy volunteers and surgical patients after treatment with stanazolol Thromb Res 33 1984 297 304
11. T. Helfman, and V. Falanga Stanozolol as a novel therapeutic agent in dermatology J Am Acad Dermatol 33 1995 254 258
12. V. De Stefano, G. Leone, L. Teofili, R. Ferrelli, G. Pollari, and V. Antonini Transient ischemic attack in a patient with congenital protein-C deficiency during treatment with stanozolol Am J Hematol 29 1988 12